P6L8
RCMGi004-B
General
Cell Line |
|
| hPSCreg name | RCMGi004-B |
| Cite as: | RCMGi004-B (RRID:CVCL_A1WP) |
| Alternative name(s) |
P6L8
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
RCMGi011-B (P10L2) Donor diseases: Mucopolysaccharidosis Type IVB autosomal recessive nonsyndromic deafness 12 RCMGi011-A (P10L1) Donor diseases: Mucopolysaccharidosis Type IVB autosomal recessive nonsyndromic deafness 12 |
| Last update | 15th April 2022 |
| User feedback | |
Provider |
|
| Generator | Research Centre for Medical Genetics (RCMG) |
External Databases |
|
| BioSamples | SAMEA7361093 |
| Cellosaurus | CVCL_A1WP |
| Wikidata | Q105510724 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 25-29 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA7211807 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | FSBSI RCMG Ethics Committee |
| Approval number | Protocol # 1 from 28.01.2016 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | FSBSI RCMG Ethics Committee |
| Approval number | Protocol # 1 from 28.01.2016 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type | |
| Source cell origin |
An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.
Synonyms
|
| Age of donor (at collection) | 25-29 |
| Collected in | 2018 |
| Passage number reprogrammed | 4 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | ReproRNA™-OKSGM kit |
| Genes | |
| Is reprogramming vector detectable? |
Unknown |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Vitronectin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
|||||
| SSEA-4 |
Yes |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| CD105 |
Yes |
| Desmin |
Yes |
| fibronectin 1 |
Yes |
Morphology
CD105 + DAPI
Desmin
Fibronectin
In vitro spontaneous differentiation
| Marker | Expressed |
| tubulin beta class I |
Yes |
| Vimentin |
Yes |
Morphology
Vimentin + DAPI
Tubulin
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.